Laurence Slembrouck

Laurence Slembrouck

Auto-generated profile, based on publicly available information

Laurence Slembrouck

Department of Oncology, University Hospitals Leuven, KU Leuven, University of Leuven, 3000, Louvain, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in The Oncologist
Verified
Journal Article
Open access
PDF file
KAKathleen Van Asten
Kathleen Van Asten
LSLaurence Slembrouck
Laurence Slembrouck
SOSiel Olbrecht
Siel Olbrecht
LJLynn Jongen
Lynn Jongen
OBOlivier Brouckaert
Olivier Brouckaert
Patrick NevenPatrick Neven
Patrick Neven
Background: In estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER-2) negative breast cancers, the progesterone receptor (PR) is an independent prognostic marker. Little is known about the prognostic value of PR by tumor grade. We assessed this in two independent datasets. Patients and Methods: Women with primary operable, invasive ER+ HER-2 negative breast cancer diagnosed between 2000 and 2012, treated at University Hospitals Leuven, were included. We assessed the association of PR status and subtype (grade 1–2 vs. grade 3) with distant recurrence-free interval (DRFI) and breast cancer-specific survival. The interaction between PR status and subtype was investigated, and associations of PR status by subtype were calculated. The BIG 1-98 data set was used for validation. Results: In total, 4,228 patients from Leuven and 5,419 from BIG 1-98 were analyzed. In the Leuven cohort, the adjusted hazard ratio (HR) of PR-positive versus PR-negative tumors for DRFI was 0.66 (95% confidence interval [CI], 0.50–0.89). For the interaction with subtype (p = .34), the HR of PR status was 0.79 (95% CI, 0.61–1.01) in luminal A-like and 0.59 (95% CI, 0.46–0.76) in luminal B-like tumors. In luminal A-like tumors, observed 5-year cumulative incidences of distant recurrence were 4.1% for PR-negative and 2.8% for PR-positive tumors, and in luminal B-like 18.7% and 9.2%, respectively. In the BIG 1-98 cohort, similar results were observed; for the interaction with subtype (p = .12), the adjusted HR of PR status for DRFI was 0.88 (95% CI, 0.57–1.35) in luminal A-like and 0.58 (95% CI, 0.43–0.77) in luminal B-like tumors. Observed 5-year cumulative incidences were similar. Conclusion: PR positivity may be more protective against metastatic relapse in luminal B-like versus luminal A-like breast cancer, but no strong conclusions can be made. In absolute risk, results suggest an absent PR is clinically more important in high compared with low proliferative ER+ HER-2 negative tumors. Implications for Practice: An absent progesterone receptor (PR) predicts a worse outcome in women treated for an estrogen receptor-positive, human epidermal growth factor receptor 2 negative breast cancer. As low proliferative tumors lacking PR are now also classified high risk, the prognostic value of PR across risk groups was studied. Despite a negative test for interaction of the prognostic value of PR by tumor grade, the magnitude of an absent PR on breast cancer relapse is much larger in high than in low proliferative breast cancers.

1 April 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MBMieke Rosalie Van Bockstal
Mieke Rosalie Van Bockstal
KLKathleen Lambein
Kathleen Lambein
ASAnn Smeets
Ann Smeets
LSLaurence Slembrouck
Laurence Slembrouck
PNPatrick Neven
Patrick Neven
GFGiuseppe Floris
Giuseppe Floris

1 July 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
LSLaurence Slembrouck
Laurence Slembrouck
IBIsabelle Vanden Bempt
Isabelle Vanden Bempt
HWHans Wildiers
Hans Wildiers
ASAnn Smeets
Ann Smeets
ARAnne Sophie Van Rompuy
Anne Sophie Van Rompuy
GFGiuseppe Floris
Giuseppe Floris

1 December 2019 in Translational Oncology
Verified
Journal Article
Open access
LSLaurence Slembrouck
Laurence Slembrouck
LDLauren Darrigues
Lauren Darrigues
CLCecile Laurent
Cecile Laurent
LMLorenza Mittempergher
Lorenza Mittempergher
LDLeonie Jmj Delahaye
Leonie Jmj Delahaye
GFGiuseppe Floris
Giuseppe Floris
A previously developed and centrally validated MammaPrint® (MP) and BluePrint® (BP) targeted RNA next-generation sequencing (NGS) kit was implemented and validated in two large academic European hospitals. Additionally, breast cancer molecular subtypes by MP and BP RNA sequencing were compared with immunohistochemistry (IHC). Patients with early breast cancer diagnosed at University Hospitals Leuven and Curie Institute Paris were prospectively included between September 2017 and January 2018. Formalin-fixed paraffin-embedded tissue sections were analyzed with MP and BP NGS technology at the beta sites and with both NGS and microarray technology at Agendia. Raw NGS data generated on Illumina MiSeq instruments at the beta sites were interpreted and compared with NGS and microarray data at Agendia. MP and BP NGS molecular subtypes were compared to surrogate IHC breast cancer subtypes. Equivalence of MP and BP indices was determined by Pearson's correlation coefficient. Acceptable limits were defined a priori, based on microarray data generated at Agendia between 2012 and 2016. The concordance, the Negative Percent Agreement and the Positive Percent Agreement were calculated based on the contingency tables and had to be equal to or higher than 90%. Out of 124 included samples, 48% were MP Low and 52% High Risk with microarray. Molecular subtypes were BP luminal, HER2 or basal in 82%, 8% and 10% respectively. Concordance between MP microarray at Agendia and MP NGS at the beta sites was 91.1%. Concordance of MP High and Low Risk classification between NGS at the beta sites and NGS at Agendia was 93.9%. Concordance of MP and BP molecular subtyping using NGS at the beta sites and microarray at Agendia was 89.5%. Concordance between MP and BP NGS subtyping, and IHC was 71.8% and 76.6%, for two IHC surrogate models. The MP/BP NGS kit was successfully validated in a decentralized setting.

5 September 2018 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
GHGriet Hoste
Griet Hoste
LSLaurence Slembrouck
Laurence Slembrouck
LJLynn Jongen
Lynn Jongen
KPKevin Punie
Kevin Punie
TMTom Matton
Tom Matton
Patrick NevenPatrick Neven
Patrick Neven

12 January 2019 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
GHGriet Hoste
Griet Hoste
LSLaurence Slembrouck
Laurence Slembrouck
LJLynn Jongen
Lynn Jongen
KPKevin Punie
Kevin Punie
TMTom Matton
Tom Matton
Patrick NevenPatrick Neven
Patrick Neven
Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.